logo-loader
viewGenedrive PLC

Director/PDMR Shareholding

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ay{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ay{}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-align: center; text-autospace: none}span.cx{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;layout-grid-mode:char;text-autospace:none}table.db{width:461.15pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.ct{width:17.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 1.45pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none}td.cr{width:422.85pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none} td.co{width:17.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.de{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 36.9pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none; text-indent: -36.9pt}span.cq{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}td.cl{width:98.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.df{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none}span.cn{font-size: 10.0pt;font-family:"Arial","sans-serif";color:black}td.ck{width:313.35pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dg{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none}p.dh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-autospace: none}p.di{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-autospace: none} td.ci{width:422.85pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-autospace: none}p.dk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; margin-left: 18.0pt; margin-right: 0cm; margin-top: 0cm; text-align: center; text-autospace: none; text-indent: -18.0pt}p.dl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-autospace: none}span.cf{font-size: 10.0pt;font-family:"Arial","sans-serif"}table.dm{border-collapse:collapse;border:none}td.cc{width:67.2pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; layout-grid-mode: char; line-height: normal; margin-bottom: 0cm; text-align: right; text-autospace: none}td.cb{width:67.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ca{width:67.2pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt} td.bz{width:67.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom: .0001pt;text-indent:-18.0pt;line-height:normal;layout-grid-mode:char; text-autospace:none}span.bx{font-size:10.0pt;font-family:Symbol; color:black}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom: .0001pt;text-indent:-18.0pt;line-height:normal;layout-grid-mode:char; text-autospace:none}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.bu{font-family:"Arial","sans-serif";color:black}p.dq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:10.0pt;text-align:justify;line-height:16.5pt}span.dr{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}table.ds{width:455.25pt;margin-left:-10.8pt;border-collapse:collapse}td.br{width:212.65pt;padding:0cm 5.4pt 0cm 5.4pt} p.ad,li.ad,div.ad{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.dt{color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold}td.bo{width:212.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.du{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:10.0pt;line-height:16.5pt}span.dv{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}span.bn{color:#212721}p.ah,li.ah,div.ah{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.dw{font-size:10.0pt;font-family:"Arial","sans-serif"; color:#212721}p.dx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:1.0pt;line-height:11.55pt}tr.bi{height:28.75pt} td.bk{width:212.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}td.bj{width:212.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}span.dy{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}tr.bd{height:26.35pt}td.bg{width:212.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.35pt}p.dz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.ea{font-size: 10.0pt;font-family:"Arial","sans-serif"}td.be{width:212.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.35pt}p.eb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.bf{font-size:10.0pt;font-family: "Arial","sans-serif";color:#212721} p.ec{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}p.ed{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top: 0cm; text-align: right}span.bq{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}p.ee{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-19.25pt;margin-bottom:5.0pt; margin-left:0cm}span.ef{color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; font-weight: bold}p.eg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.ba{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}span.eh{font-size: 10.0pt;font-family:"Arial","sans-serif";color:black} /**/
RNS Number : 4173U
Genedrive PLC
22 November 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 48,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 21p per share.

 

Following these purchases, Dr Gilham is interested in 365,674 Ordinary Shares, 1.08% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.         

Details of the person discharging managerial responsibilities / person closely associated

a.         

Name

Ian Gilham

 

 

2.         

Reason for the notification

a.         

Position/status

Non-Executive Chairman

a.         

Initial notification

/Amendment

Initial notification

3.  

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.         

Name

genedrive plc

b.         

LEI

213800ZYODIRZ87Y4K14

4.         

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.         

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.         

Nature of the transaction

Purchase

c.         

Price(s) and volume(s)

 

Price(s)

Volume(s)

21p

48,000

 

d.         

Aggregated information

·      Aggregated volume

·      Price

 

 

N/A

 

e.         

Date of the transaction

2019-11-22; UTC time

f.         

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO


Matthew Fowler: CFO




Peel Hunt LLP

+44 (0)207 418 8900

James Steel


Oliver Jackson




Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes




Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHEALFAADPNFFF

Quick facts: Genedrive PLC

Price: 21.5

Market: AIM
Market Cap: £7.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Genedrive reports 'high clinical accuracy' for its AIHL...

Headlines from Proactive UK newsroom. Genedrive (LON:GDR) has scored 100% diagnostic sensitivity and 100% specificity in a test of its assay kit to identify babies at risk of hearing loss from the use of antibiotic gentamicin. The clinical study was based on 303 samples. Gold miner...

1 week, 1 day ago